|
1.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 -  10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
2.
|
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
|
3.
|
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 - 10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
|
4.
|
|
|
5.
|
|
9 p, 686.2 KB |
The relapsed acute lymphoblastic leukemia network (ReALLNet) : a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)
/
Velasco, Pablo (Hospital Universitari Vall d'Hebron) ;
Bautista, Francisco (Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands) ;
Rubio, Alba (Hospital Infantil Universitario Niño Jesús) ;
Aguilar, Yurena (Hospital Miguel Servet Hospital) ;
Rives, Susana (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Dapena, Jose L (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Pérez, Antonio (Universidad Autónoma de Madrid) ;
Ramirez, Manuel (Fundación Para La Investigación Biomédica Hospital Infantil Universitario Niño Jesús) ;
Saiz-Ladera, Cristina (Fundación Para La Investigación Biomédica Hospital Infantil Universitario Niño Jesús) ;
Izquierdo, Elisa (La Paz University Hospital) ;
Escudero, Adela (La Paz University Hospital) ;
Camós, Mireia (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Vega-García, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Ortega, Margarita (Vall d'Hebron Institut d'Oncologia) ;
Hidalgo-Gómez, Gloria (Vall d'Hebron Institut d'Oncologia) ;
Palacio, Carlos (Vall d'Hebron Institut d'Oncologia) ;
Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Montero, Joan (Universitat de Barcelona) ;
Romecín, Paola A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zazo, Santiago (Universidad Politécnica de Madrid) ;
Alvarez, Federico (Universidad Politécnica de Madrid) ;
Parras, Juan (Universidad Politécnica de Madrid) ;
Ortega-Sabater, Carmen (University of Castilla-La Mancha) ;
Chulián, Salvador (Universidad de Cádiz) ;
Rosa, María (Universidad de Cádiz) ;
Cirillo, Davide (Barcelona Supercomputing Center) ;
García, Elena (Fundación Para La Investigación Biomédica Hospital Infantil Universitario Niño Jesús) ;
García, Jorge (Fundación Para La Investigación Biomédica Hospital Infantil Universitario Niño Jesús) ;
Manzano-Muñoz, Albert (Universitat de Barcelona) ;
Minguela, Alfredo (Instituto Murciano de Investigación Biosanitaria) ;
Fuster, Jose L. (Instituto Murciano de Investigación Biosanitaria)
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with survival rates exceeding 85%. However, 15% of patients will relapse; consequently, their survival rates decrease to below 50%. [...]
2023 - 10.3389/fped.2023.1269560
Frontiers in Pediatrics, Vol. 11 (september 2023)
|
|
|
6.
|
|
10 p, 3.3 MB |
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia : results of the BURKIMAB14 trial
/
Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garcia-Calduch, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sirvent, Maialen (Hospital Universitario de Donostia) ;
Buendia, Buenaventura (Hospital Universitario 12 de Octubre) ;
Cervera, Marta (Institut Catala d'Oncologia-Hospital Joan XXIII) ;
Luzardo, Hugo (Hospital Universitario de Gran Canaria Dr. Negrin) ;
Hernandez-Rivas, Jesus Maria (Hospital Universitario de Salamanca) ;
Sitges, Marta (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcia-Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Bastos-Oreiro, Mariana (Hospital General Universitario Gregorio Marañón) ;
De Llano, Maria Paz Queipo (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, Pilar (Hospital Universitario de Fuenlabrada. Madrid) ;
Torrent, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal) ;
Garcia-Guinon, Antonni (Hospital Universitari Arnau de Vilanova) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Terol, Maria José (Hospital Clinico Universitario de Valencia) ;
Bergua, Juan Miguel (Hospital San Pedro de Alcántara) ;
Garcia-Noblejas, Ana (Hospital Universitario de La Princesa) ;
Barrenetxea, Cristina (Hospital Universitario Basurto) ;
Llorente, Laura (Hospital Universitario HM Sanchinarro) ;
Garcia-Belmonte, Daniel (Hospital Universitario La Zarzuela) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Cladera, Antonia (Hospital Universitari Son Llatzer) ;
Mercadal, Santiago (Institut Català d'Oncologia) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. [...]
2024 - 10.3324/haematol.2023.283342
Haematologica, Vol. 109 Núm. 2 (january 2024) , p. 543-552
|
|
|
7.
|
|
11 p, 771.0 KB |
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?
/
Cabrera Serrano, Antonio José (Instituto de Investigación Sanitaria de Granada) ;
Sánchez Maldonado, José Manuel (Instituto de Investigación Sanitaria de Granada) ;
ter Horst, Rob (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) ;
Macauda, Angelica (German Cancer Research Center) ;
García Martín, Paloma (Hospital Campus de la Salud (Granada)) ;
Benavente, Yolanda (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Landi, Stefano (Department of Biology. University of Pisa) ;
Clay-Gilmour, Alyssa (Department of Epidemiology & Biostatistics. Arnold School of Public Health. University of South Carolina) ;
Niazi, Yasmeen (Hopp Children's Cancer Center) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rodriguez-Sevilla, Juan Jose (Department of Leukemia. The University of Texas MD Anderson Cancer Center) ;
Pérez, Eva María (Hospital Campus de la Salud) ;
Maffei, Rossana (University of Modena and Reggio Emilia) ;
Blanco, Gonzalo (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Giaccherini, Matteo (Department of Biology. University of Pisa) ;
Cerhan, James R. (Department of Quantitative Health Sciences. Mayo Clinic) ;
Marasca, Roberto (Department of Medical and Surgical Sciences. University of Modena and Reggio Emilia. AOU Policlinico) ;
Lopez Nevot, Miguel Angel (Hospital Universitario Virgen de las Nieves (Granada)) ;
Chen-Liang, Tzu Hua (Hospital Universitario Morales Meseguer (Múrcia)) ;
Thomsen, Hauke (MSB Medical School Berlin) ;
Gámez, Irene (Hematology Department. Morales Meseguer University Hospital) ;
Campa, Daniele (Department of Biology. University of Pisa) ;
Moreno Aguado, Víctor (Facultat de Medicina. Universitat de Barcelona) ;
de Sanjosé, Silvia (Universitat de Barcelona) ;
Marcos-Gragera, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Álvarez, María Flor (Instituto de Investigación Biomédica de Salamanca) ;
Dierssen-Sotos, Trinidad (Universidad de Cantabria) ;
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ;
Butrym, Aleksandra (Department of Cancer Prevention and Therapy. Medical University of Wrocław) ;
Norman, Aaron D. (Department of Quantitative Health Sciences. Mayo Clinic) ;
Luppi, Mario (University of Modena and Reggio Emilia) ;
Slager, Susan L. (Mayo Clinic) ;
Hemminki, Kari (Charles University in Prague) ;
Li, Yang (Hannover Medical School) ;
Berndt, Sonja I. (National Institutes of Health (Estats Units d'Amèrica)) ;
Casabonne, Delphine (Universitat de Barcelona) ;
Alcoceba, Miguel (Instituto de Investigación Biomédica de Salamanca) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Netea, Mihai G. (Department for Immunology & Metabolism. University of Bonn) ;
Försti, Asta (Hopp Children's Cancer Center) ;
Canzian, Federico (German Cancer Research Center) ;
Sainz, Juan (Department of Biochemistry and Molecular Biology. Universidad de Granada)
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of GWAS-identified risk variants to predict disease progression and patient survival remains unexplored. [...]
2023 - 10.3390/ijms24098005
International journal of molecular sciences, Vol. 24 Núm. 9 (may 2023) , p. 8005
|
|
|
8.
|
|
5 p, 178.9 KB |
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation : A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico
/
Orti, Guillermo (Grupo Español de Trasplante Hematopoyetico) ;
Sanz, Jaime (Grupo Español de Trasplante Hematopoyetico) ;
Bermudez, Arancha (Grupo Español de Trasplante Hematopoyetico) ;
Caballero, Dolores (Grupo Español de Trasplante Hematopoyetico) ;
Martinez, Carmen (Grupo Español de Trasplante Hematopoyetico) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Cabrera Marin, José R. (Grupo Español de Trasplante Hematopoyetico) ;
Espigado, Ildefonso (Grupo Español de Trasplante Hematopoyetico) ;
Solano, Carlos (Grupo Español de Trasplante Hematopoyetico) ;
Ferrà, Christelle (Grupo Español de Trasplante Hematopoyetico) ;
García-Noblejas, Ana (Grupo Español de Trasplante Hematopoyetico) ;
Jimenez, Santiago (Grupo Español de Trasplante Hematopoyetico) ;
Sampol, Antonia (Grupo Español de Trasplante Hematopoyetico) ;
Yañez, Lucrecia (Grupo Español de Trasplante Hematopoyetico) ;
García-Gutiérrez, Valentin (Grupo Español de Trasplante Hematopoyetico) ;
Pascual, Maria Jesus (Grupo Español de Trasplante Hematopoyetico) ;
Jurado, Manuel (Grupo Español de Trasplante Hematopoyetico) ;
Moraleda, José M. (Grupo Español de Trasplante Hematopoyetico) ;
Valcarcel, David (Grupo Español de Trasplante Hematopoyetico) ;
Sanz, Miguel A. (Grupo Español de Trasplante Hematopoyetico) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Duarte, Rafael F. (Grupo Español de Trasplante Hematopoyetico) ;
Universitat Autònoma de Barcelona
Allogeneic stem cell transplantation (allo-HCT) represents the most effective immunotherapy for acute myeloid leukemia (AML) and myeloid malignancies. However, disease relapse remains the most common cause of treatment failure. [...]
2016 - 10.1016/j.bbmt.2015.11.012
Biology of blood and marrow transplantation, Vol. 22 Núm. 3 (january 2016) , p. 584-588
|
|
|
9.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
10.
|
|
22 p, 2.9 MB |
Advancing CART therapy for acute myeloid leukemia : recent breakthroughs and strategies for future development
/
Pérez-Amill, Lorena (Department of Immunology. Centre de Diagnòstic Biomèdic (CDB). Hospital Clínic de Barcelona) ;
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Delgado, Julio (Universitat de Barcelona) ;
Esteve, Jordi (Universitat de Barcelona) ;
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Klein-González, Nelia (Hospital Clínic i Provincial de Barcelona)
Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological malignancies and the need of new treatments for relapsed and refractory AML. [...]
2023 - 10.3389/fimmu.2023.1260470
Frontiers in immunology, Vol. 14 (2023) , p. 1260470
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
